<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5157">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01165554</url>
  </required_header>
  <id_info>
    <org_study_id>GE-067-007</org_study_id>
    <nct_id>NCT01165554</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels</brief_title>
  <official_title>A Principal Open-Label Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Amyloid Levels Determined Post-Mortem</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>i3 Statprobe</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GE Healthcare</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the level of association between quantitative regional estimates of brain
      uptake of [18F]flutemetamol and quantitative immunohistochemical regional estimates of brain
      levels of amyloid estimated from post-mortem analysis of corresponding brain tissue samples.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>The Sensitivity of Blinded Visual Interpretations of [18F]Flutemetamol Positron Emission Tomography (PET) Images Without Anatomic Brain Images for Detecting Brain Fibrillar Amyloid β.</measure>
    <time_frame>Post flutemetamol administration.</time_frame>
    <safety_issue>No</safety_issue>
    <description>A calculation used to assess Sensitivity was (Number of Blinded Reads determined abnormal by Reader &quot;N&quot;) divided by the (Total number of abnormal participants).
Blinded visual interpretations of [18F]flutemetamol Positron Emission Tomography (PET) images without anatomic brain images for detecting brain fibrillar amyloid β.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blinded Visual Interpretation of Each Subject's Flutemetamol F 18 Injection Brain PET Images as Normal, Without Anatomic Brain Images.</measure>
    <time_frame>Post Flutemetamol administrations</time_frame>
    <safety_issue>No</safety_issue>
    <description>A calculation used to assess Specificity was (Number of Blinded Reads determined normal by Reader &quot;N&quot;) divided by the (Total number of normal participants).
Blinded visual interpretation of each subject's Flutemetamol F 18 Injection brain PET images as normal, without anatomic brain images.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blinded Visual Interpretation of Each Subject's Flutemetamol F 18 Injection Brain PET Images as Abnormal, With Anatomic CT Brain Images for Reference.</measure>
    <time_frame>Post flutemetamol administration.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blinded visual interpretation of each subject's Flutemetamol F 18 Injection brain PET images as abnormal, with anatomic CT brain images for reference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blinded Visual Interpretation of Each Subject's Flutemetamol F 18 Injection Brain PET Images as Normal, With Anatomic CT Brain Images for Reference.</measure>
    <time_frame>Post flutemetamol administration.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blinded visual interpretation of each subject's Flutemetamol F 18 Injection brain PET images as normal, with anatomic CT brain images for reference.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">203</enrollment>
  <condition>Brain Fibrillarab Levels</condition>
  <arm_group>
    <arm_group_label>[18F] Flutemetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F] Flutemetamol</intervention_name>
    <description>Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection.</description>
    <arm_group_label>[18F] Flutemetamol</arm_group_label>
    <other_name>AH110690</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has a short life expectancy (approximately 1 year or less) as estimated
             by the Investigator.

          -  The subject is 70 years of age or older if cognitively normal, or 55 years of age or
             older if terminal because of dementia.

          -  The subject's general health is adequate to undergo the study procedures.

        Exclusion Criteria:

          -  The subject has a contraindication for PET.

          -  The subject has a known or suspected hypersensitivity/allergy to [18F]flutemetamol or
             to any of the excipients.

          -  The subject is unable to tolerate or cooperate with study procedures.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Sherwin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>GE Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GE Healthcare</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 8, 2013</lastchanged_date>
  <firstreceived_date>June 21, 2010</firstreceived_date>
  <firstreceived_results_date>May 7, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyloid</keyword>
  <keyword>PET-Positron Emission Tomography</keyword>
  <keyword>SUVR-Standard uptake value ratios</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study started on May, 2010 and ended on November 2011.</recruitment_details>
      <pre_assignment_details>23 subjects withdrew from study prior to dosing of the product.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Flutemetamol Injection</title>
          <description>[18F]flutemetamol (less than 10 microgram (ug) flutemetamol). The nominal activity of a single administration of [18F]flutemetamol was 185 to 370 megabecquerels (MBq).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="203">This was the number of subjects that started the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Flutemetamol Injection</title>
          <description>[18F]flutemetamol (less than 10 microgram (ug) flutemetamol). The nominal activity of a single administration of [18F]flutemetamol was 185 to 370 megabecquerels (MBq).</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="180"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="165"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="79.9" spread="9.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="103"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="77"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="168"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>United Kingdom</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Sensitivity of Blinded Visual Interpretations of [18F]Flutemetamol Positron Emission Tomography (PET) Images Without Anatomic Brain Images for Detecting Brain Fibrillar Amyloid β.</title>
        <description>A calculation used to assess Sensitivity was (Number of Blinded Reads determined abnormal by Reader &quot;N&quot;) divided by the (Total number of abnormal participants).
Blinded visual interpretations of [18F]flutemetamol Positron Emission Tomography (PET) images without anatomic brain images for detecting brain fibrillar amyloid β.</description>
        <time_frame>Post flutemetamol administration.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The assessments were post-mortum based on the estimates of the presence of amyloid plaque in the brain.</population>
        <group_list>
          <group group_id="O1">
            <title>Sensitivity Percentage of Abnormal Visual Reads</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Sensitivity of Blinded Visual Interpretations of [18F]Flutemetamol Positron Emission Tomography (PET) Images Without Anatomic Brain Images for Detecting Brain Fibrillar Amyloid β.</title>
            <description>A calculation used to assess Sensitivity was (Number of Blinded Reads determined abnormal by Reader &quot;N&quot;) divided by the (Total number of abnormal participants).
Blinded visual interpretations of [18F]flutemetamol Positron Emission Tomography (PET) images without anatomic brain images for detecting brain fibrillar amyloid β.</description>
            <units>Percentage of Sensitivity by Reader</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Reader 1- Abnormal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 2 - Abnormal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 3 - Abnormal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 4 - Abnormal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 5 - Abnormal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blinded Visual Interpretation of Each Subject’s Flutemetamol F 18 Injection Brain PET Images as Normal, Without Anatomic Brain Images.</title>
        <description>A calculation used to assess Specificity was (Number of Blinded Reads determined normal by Reader &quot;N&quot;) divided by the (Total number of normal participants).
Blinded visual interpretation of each subject’s Flutemetamol F 18 Injection brain PET images as normal, without anatomic brain images.</description>
        <time_frame>Post Flutemetamol administrations</time_frame>
        <safety_issue>No</safety_issue>
        <population>The assessment was done post-mortum based on the estimates of the presence of amyloid plaque in the brain.</population>
        <group_list>
          <group group_id="O1">
            <title>Specificity Percentage of Normal Visual Reads</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Blinded Visual Interpretation of Each Subject’s Flutemetamol F 18 Injection Brain PET Images as Normal, Without Anatomic Brain Images.</title>
            <description>A calculation used to assess Specificity was (Number of Blinded Reads determined normal by Reader &quot;N&quot;) divided by the (Total number of normal participants).
Blinded visual interpretation of each subject’s Flutemetamol F 18 Injection brain PET images as normal, without anatomic brain images.</description>
            <units>Percentage of Specificity by Reader</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Reader 1 - Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 2 - Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 3 - Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 4 - Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 5 - Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blinded Visual Interpretation of Each Subject’s Flutemetamol F 18 Injection Brain PET Images as Abnormal, With Anatomic CT Brain Images for Reference.</title>
        <description>Blinded visual interpretation of each subject’s Flutemetamol F 18 Injection brain PET images as abnormal, with anatomic CT brain images for reference.</description>
        <time_frame>Post flutemetamol administration.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Sensitivity-Abnormal Visual Reads</title>
            <description>[18F]flutemetamol (less than 10 microgram (ug) flutemetamol). The nominal activity of a single administration of [18F]flutemetamol was 185 to 370 megabecquerels (MBq).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Blinded Visual Interpretation of Each Subject’s Flutemetamol F 18 Injection Brain PET Images as Abnormal, With Anatomic CT Brain Images for Reference.</title>
            <description>Blinded visual interpretation of each subject’s Flutemetamol F 18 Injection brain PET images as abnormal, with anatomic CT brain images for reference.</description>
            <units>Percent of Sensitivity-Abnormal Reads</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Reader 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="91" lower_limit="78" upper_limit="97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="95" lower_limit="84" upper_limit="99"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98" lower_limit="88" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="91" lower_limit="78" upper_limit="97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="91" lower_limit="77" upper_limit="97"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blinded Visual Interpretation of Each Subject’s Flutemetamol F 18 Injection Brain PET Images as Normal, With Anatomic CT Brain Images for Reference.</title>
        <description>Blinded visual interpretation of each subject’s Flutemetamol F 18 Injection brain PET images as normal, with anatomic CT brain images for reference.</description>
        <time_frame>Post flutemetamol administration.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Specificity-Normal Visual Reads</title>
            <description>[18F]flutemetamol (less than 10 microgram (ug) flutemetamol). The nominal activity of a single administration of [18F]flutemetamol was 185 to 370 megabecquerels (MBq).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Blinded Visual Interpretation of Each Subject’s Flutemetamol F 18 Injection Brain PET Images as Normal, With Anatomic CT Brain Images for Reference.</title>
            <description>Blinded visual interpretation of each subject’s Flutemetamol F 18 Injection brain PET images as normal, with anatomic CT brain images for reference.</description>
            <units>Percent of Specificity-Normal Reads</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Reader 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92" lower_limit="74" upper_limit="99"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88" lower_limit="69" upper_limit="98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56" lower_limit="35" upper_limit="76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88" lower_limit="69" upper_limit="98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92" lower_limit="74" upper_limit="99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Flutemetamol Injection</title>
          <description>[18F]flutemetamol (less than 10 microgram (ug) flutemetamol). The nominal activity of a single administration of [18F]flutemetamol was 185 to 370 megabecquerels (MBq).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Senile Dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Change in Mental Status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Paul Sherwin</name_or_title>
      <organization>GE Healthcare</organization>
      <phone>1-609-514-6820</phone>
      <email>paulsherwin@ge.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
